Advertisement
UK markets closed

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • CRUDE OIL

    78.40
    -0.08 (-0.10%)
     

  • GOLD FUTURES

    2,321.80
    -9.40 (-0.40%)
     

  • DOW

    38,869.15
    +16.88 (+0.04%)
     

  • Bitcoin GBP

    50,306.00
    -351.75 (-0.69%)
     

  • CMC Crypto 200

    1,309.37
    -55.76 (-4.08%)
     

  • NASDAQ Composite

    16,324.35
    -24.89 (-0.15%)
     

  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

BUZZ-Smith & Nephew: recovering poise

Reuters - UK Focus

** Artificial joint maker Smith & Nephew (LSE: SN.L - news) bounces off recent lows as Barclays (LSE: BARC.L - news) lifts its rating on the stock to "overweight" vs "equal weight" on valuation grounds and with the bank seeing scope for M&A opportunites.

** S&N up 1.7 pct at 978.62 pence, among top performing stocks on the FTSE 100. Move (NasdaqGS: MOVE - news) closes recent gap lower, and trims losses since June peak to 14 pct.

** Barclays sees two scenarios which could push S&N closer to its blue-sky valuation of 1,500 pence; either S&N deploys $2-3 bln on acquisitions from 2016, which could bring a 10 pct EPS uplift, or S&N is part of a sector consolidation.

** Stock recently hit 6-month lows, suffering along with peers as AbbVie (Xetra: 4AB.DE - news) 's planned Shire inversion deal fell apart.

** Barclays highlights inversion benefits are not the only motivation for strategic healthcare deals. (RM (LSE: RM.L - news) :tricia.wright1.thomsonreuters.com@reuters.net)